NIH Funding Opportunities (RSS Feed)
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional)
Funding Opportunity RFA-CA-21-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
For more information, visit the Sponsor URL.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
Funding Opportunity RFA-CA-21-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
For more information, visit the Sponsor URL.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
Funding Opportunity RFA-CA-21-011 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
For more information, visit the Sponsor URL.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
Funding Opportunity RFA-CA-21-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
For more information, visit the Sponsor URL.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-21-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.
For more information, visit the Sponsor URL.
Request for Information (RFI) Regarding Opportunities for New National Programs at the National Cancer Institutes (NCI) Frederick National Laboratory for Cancer Research
Notice NOT-CA-21-018 from the NIH Guide for Grants and Contracts
For more information, visit the Sponsor URL.
Notice of Intent to Reissue Funding Opportunity Announcements "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)" to Permit Resubmissions
Notice NOT-OD-21-034 from the NIH Guide for Grants and Contracts
For more information, visit the Sponsor URL.
Notice Extending Expiration Date and Adding Receipt Date for PAR-18-324: Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)
Notice NOT-OD-21-032 from the NIH Guide for Grants and Contracts
For more information, visit the Sponsor URL.
Notice Extending Expiration Date and Adding Receipt Date for PAR-18-307: Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)
Notice NOT-OD-21-031 from the NIH Guide for Grants and Contracts
For more information, visit the Sponsor URL.
Reconfiguration of GenitoUrinary Development Molecular Anatomy Project (GUDMAP) /(Re)Building A Kidney (RBK) Data Hub (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-20-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications for a consolidated Data Hub for the GenitoUrinary Development Molecular Anatomy Project (GUDMAP) and the (Re)Building a Kidney (RBK) consortium. The GUDMAP/RBK Data Hub will have both scientific and administrative responsibilities, including the operation of a searchable web-based data repository. The Data Hub will implement FAIR (Findable, Accessible, Interoperable, and Reusable) principles and have appropriate domain expertise, such as in bioinformatics, website and software development, biocuration and ontology development (including specific expertise in appropriate organ anatomy and physiology), and workshop planning and administration. The Data Hub will also oversee an Opportunity Pool Program to promote collaboration in the formation of new partnerships and to actively enhance the database capabilities.
For more information, visit the Sponsor URL.
- ‹ previous
- 107 of 785
- next ›